Formulation: A lyophilized powder
Formal Name: L-phenylalanyl-L-leucyl-L-phenylalanyl-L-glutaminyl-L-prolyl-L-glutaminyl-L-arginyl-L-phenylalaninamide, trifluoroacetate salt
Purity: ≥95%
Formula Markup: C54H76N14O10 • XCF3COOH
Formula Weight: 1081,3
Shelf life (days): 1460
CAS Number: 99566-27-5
Notes: Neuropeptide FF (NPFF) is a peptide expressed in the brain and spinal cord that shares a precursor protein with neuropeptide AF.{38823} NPFF is expressed primarily in the posterior pituitary, hypothalamus, and medulla. It is an agonist at NPFF1 and NPFF2 receptors (Kis = 2.82 and 0.21 nM, respectively, for human recombinant receptors) that inhibits forskolin-induced cAMP production in CHO cells (EC50s = 236 and 2.3 nM, respectively).{38824} NPFF activates parvocellular neurons in the paraventricular nucleus (PVN) of the hypothalamus to stimulate oxytocin release from their projections in the brain stem, thereby regulating baroreflex control of heart rate.{38825} However, it inhibits magnocellular PVN neurons by enhancing GABAergic input. It is also found in plasma and exogenous administration briefly increases mean arterial pressure (MAP) by 40 mm Hg in rats, an effect that is only partially blocked by the norepinephrine competitor guanethidine (Item No. 16217) and the α1-adrenergic receptor antagonist prazosin (Item No. 15023).{38826} NPFF has anti-opioid effects in rodent models, inhibiting morphine-induced analgesia and inducing abstinence in morphine-tolerant rats.{38823,38827} It also inhibits acquisition of conditioned place preference to cocaine in rats when administered at doses of 10 and 20 nmol.{38828}
English
Deutsch
